HOME >> BIOLOGY >> NEWS
Heart has enough oxygen to survive hypothermia, CPR crucial

ic groups and a control group. They exposed one hypothermic group to 15C (59F) for one hour before rewarming. They exposed the second group to 15C, but for five hours. The control group was kept at normal temperature, 37C (98.6F). The researchers followed the hemodynamic changes during hypothermia and rewarming and later examined the rats' heart cells.

When core body temperature was lowered to 15C, both hypothermic groups experienced a similar reduction in circulating blood volume. And both showed that the physiological mechanisms that help transport oxygen and help unload oxygen from hemoglobin were working. "As a consequence, oxygen supply was not a limiting factor for survival in the present experiments," the authors wrote.

The rats in the one-hour group spontaneously normalized their blood pressure, cardiac output and heart rate after they were rewarmed, Tveita noted. However, the rats in the five-hour group, which were significantly more likely to experience heart failure during rewarming, experienced substantial lowering of cardiac output and other cardiac functions.

"We conclude that the heart failure we see after rewarming is not due to a lack of oxygen supply or oxygen transportation because unloading of oxygen at the cell level from hemoglobin is functioning," Tveita stated. Thus, it appears that the problem comes as a result of the lower cardiac output, he added.

"Thus, efforts aimed at elevating cardiac output in this phase seem advisable in order to optimize oxygen supply, reperfuse (restore blood flow to) vascular beds (minute blood vessels) and prevent rewarming shock formation," the authors wrote

Source and funding

"Is oxygen supply a limiting factor for survival during rewarming from profound hypothermia?" by Timofei V. Kondratiev, Kristina Flemming, and Mikhail A. Sovershaev, University of Troms, Norway; Eivind S.P. Myhre, Srlandet Hospital, Kristiansand; and Torkjel Tveita, Univer
'"/>

Contact: Christine Guilfoy
cguilfoy@the-aps.org
301-634-7253
American Physiological Society
18-Jul-2006


Page: 1 2 3 4

Related biology news :

1. Hearts of male and female rainbow trout are different
2. Heart failure: Intervention possibilities from imaging programmed cell loss
3. Heart intervention doesnt outweigh medicine in study
4. International Society for Heart and Lung Transplantation 27th Annual Meeting and Scientific Sessions
5. Heart rhythm genes possible factors in SIDS
6. Hearts or tails?
7. Heart smart: new drug improves blood flow
8. Defusing a time bomb: Heart attack risk-detection technology developed at UH
9. Heart failure wall stress drops 38% with moderate thyroid hormone therapy
10. New studies released at the Heart Rhythm Societys Annual Meeting
11. Molecular testing impact: Heart transplant patients benefit from new technology, easier monitoring

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Heart has enough oxygen survive hypothermia CPR crucial

(Date:5/21/2013)... Illinois at Chicago College of Medicine will study gender differences ... main energy source -- and how changes in fat metabolism ... million, 4-year grant from the National Heart, Lung and Blood ... fuel for energy. These changes may play a major role ... men and women, says E. Douglas Lewandowski, director of the ...
(Date:5/21/2013)... few decades, scientists have developed many devices that can ... While generally effective, each of these treatments has drawbacks, ... study from MIT analyzes the potential usefulness of a ... and drug-releasing stents, but may pose fewer risks. With ... artery for only a brief period, during which it ...
(Date:5/21/2013)... 2013 Royal Philips Electronics (NYSE: PHG, AEX: ... portable ultrasound with Philips, industry leading Live 3D TEE, ... xMATRIX with available Live 3D TEE and ICE will ... the EuroPCR, official meeting for the European Association of ... its launch in 2012, Philips CX50 xMATRIX has been ...
Breaking Biology News(10 mins):Do men's and women's hearts burn fuel differently? 2Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2
(Date:5/21/2013)... -- First patients dosed with PSX1002, an ... using Prosonix, particle engineering platform Prosonix, an ... Respiratory Medicines by Design , has initiated a ... its effect on lung function and the safety of ... severe chronic obstructive pulmonary disease (COPD). The first two ...
(Date:5/21/2013)... by George Washington University Professor Tianshu Li provide ... small droplets is strongly size-dependent, an important conclusion ... formation of ice at the nanoscale is a ... has important implications for climate research and other ... supercooled water is generally initiated by a process ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, innovative ... Genzyme, a Sanofi company and leading biotech company, recently ... a multi-use facility in the United States. With Door ... this latest order underscores the satisfaction and success the ... device improving doorway access control. , “We recommend ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: